No Data
Unusual Options Activity: APA, IQV and Others Attract Market Bets, APA V/OI Ratio Reaches 227.3
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
What You Can Learn From Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) P/E
Neurocrine Biosciences, Inc. Selects PANTHERxRare Specialty Pharmacy for Distribution of Crenessity (Crinecerfont)
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50
Srav Reddy : You missed VSTM and